Christine N. Duncan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christine N. Duncan has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Miki Nishitani
Dana‐Farber/Boston Children's Cancer and Blood Disorders Center Boston Massachusetts USA
4 shared publications - Geoffrey D. E. Cuvelier
Department of Pediatric Oncology and Transplantation, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada
3 shared publications - Seth J. Rotz
Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, Ohio
3 shared publications Kirsten M. Williams
Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Emory University
2 shared publicationsLeslie Lehmann
Boston Children's Hospital, Dana Farber Cancer Institute
2 shared publications- Lev Gorfinkel
Division of Pediatric Hematology-Oncology, Boston Children’s Hospital, Boston, MA
2 shared publications
Latest Publications
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11)
Late Endocrine and Organ Toxicities After Treosulfan‐Based Conditioning in Pediatric Hematopoietic Cell Transplantation: A Systematic Review
Treosulfan is an alkylating agent indicated as a conditioning agent for allogeneic hematopoietic cell transplantation (HCT), with an established favorable acute toxicity profile; however, its long‐term sequelae remain incompletely characterized. This review aims to characterize the late effects following treosulfan‐based conditioning in pediatric HCT and to identify critical gaps in published evidence. This systematic review was conducted in accordance with PRISMA guidelines and prospectively registered with PROSPERO (CRD420261345072). PubMed, Embase, and the Cochrane Library were searched from inception through April 28, 2026 for studies reporting late effects in patients aged ≤ 40 years at the time of HCT who received treosulfan‐based conditioning. Risk of bias was assessed using the Newcastle–Ottawa Scale. Sixteen retrospective studies met inclusion criteria. Three studies evaluated sex hormone replacement therapy, and none of the patients receiving treosulfan required it. Treosulfan use was associated with significantly less gonadal toxicity compared to busulfan in several cohorts. Non‐gonadal endocrine or non‐endocrine late effects were reported mostly in single cohorts with no significant differences compared to busulfan. In conclusion, treosulfan‐based conditioning appears to have a meaningfully lower risk to gonadal dysfunction compared to busulfan, most prominently in patients with nonmalignant diagnoses and in females. No significant differences were observed for non‐gonadal late effects, albeit data remain limited.
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11)
Late Endocrine and Organ Toxicities After Treosulfan‐Based Conditioning in Pediatric Hematopoietic Cell Transplantation: A Systematic Review
Treosulfan is an alkylating agent indicated as a conditioning agent for allogeneic hematopoietic cell transplantation (HCT), with an established favorable acute toxicity profile; however, its long‐term sequelae remain incompletely characterized. This review aims to characterize the late effects following treosulfan‐based conditioning in pediatric HCT and to identify critical gaps in published evidence. This systematic review was conducted in accordance with PRISMA guidelines and prospectively registered with PROSPERO (CRD420261345072). PubMed, Embase, and the Cochrane Library were searched from inception through April 28, 2026 for studies reporting late effects in patients aged ≤ 40 years at the time of HCT who received treosulfan‐based conditioning. Risk of bias was assessed using the Newcastle–Ottawa Scale. Sixteen retrospective studies met inclusion criteria. Three studies evaluated sex hormone replacement therapy, and none of the patients receiving treosulfan required it. Treosulfan use was associated with significantly less gonadal toxicity compared to busulfan in several cohorts. Non‐gonadal endocrine or non‐endocrine late effects were reported mostly in single cohorts with no significant differences compared to busulfan. In conclusion, treosulfan‐based conditioning appears to have a meaningfully lower risk to gonadal dysfunction compared to busulfan, most prominently in patients with nonmalignant diagnoses and in females. No significant differences were observed for non‐gonadal late effects, albeit data remain limited.
- 24 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 887.e1-887.e16
Eculizumab for Pediatric Hematopoietic Cell Transplant–Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment
- 24 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 887.e1-887.e16
Eculizumab for Pediatric Hematopoietic Cell Transplant–Associated Thrombotic Microangiopathy: Real-World Response Rates, Predictors of Poor Response, and an Optimal Time Point for Treatment Response Assessment
- 14 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32038
Veno‐Occlusive Disease in Very Young Children: A Profile of High Morbidity With Low Mortality
Background/Objectives: Younger age is a recognized risk factor for veno‐occlusive disease (VOD), yet no prior studies have focused on diagnostic criteria and outcomes in very young children. This retrospective study compared overall survival (OS) in very young children with and without a clinical diagnosis of VOD, in addition to comparing OS for those with clinical VOD versus those who retrospectively fulfilled VOD criteria. Design/Methods: Included were patients who received their first hematopoietic stem cell transplant (HCT) for any indication at less than 4 years of age between January 1, 2016 and October 31, 2021. Three pediatric VOD criteria were retrospectively applied to subjects. Results: Of 150 HCT recipients less than 4 years old, 18 were clinically diagnosed with VOD at a median of 14 days. More patients with VOD were admitted to the ICU [79% vs. 15%, p < 0.001]. Of those with VOD, 78% required peritoneal drainage, 17% pleural effusion drainage, and 56% respiratory failure. All patients with VOD survived to discharge and to Day +100. In allo‐recipients, OS at Day +365, cumulative incidence of Grade II–IV acute graft‐versus‐host disease (aGVHD) at Day +100, and chronic graft‐versus‐host disease (cGVHD) at Day +365 were similar between those with and without VOD. Median length of stay was longer in those with VOD [60.5 vs. 38 days, p < 0.001]. More patients retrospectively met criteria for VOD than were clinically diagnosed. Conclusion: While VOD in very young children can be highly morbid, they have excellent early survival. Retrospective evaluation demonstrates that only some patients who fulfilled VOD criteria were clinically diagnosed.
- 14 September 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32038
Veno‐Occlusive Disease in Very Young Children: A Profile of High Morbidity With Low Mortality
Background/Objectives: Younger age is a recognized risk factor for veno‐occlusive disease (VOD), yet no prior studies have focused on diagnostic criteria and outcomes in very young children. This retrospective study compared overall survival (OS) in very young children with and without a clinical diagnosis of VOD, in addition to comparing OS for those with clinical VOD versus those who retrospectively fulfilled VOD criteria. Design/Methods: Included were patients who received their first hematopoietic stem cell transplant (HCT) for any indication at less than 4 years of age between January 1, 2016 and October 31, 2021. Three pediatric VOD criteria were retrospectively applied to subjects. Results: Of 150 HCT recipients less than 4 years old, 18 were clinically diagnosed with VOD at a median of 14 days. More patients with VOD were admitted to the ICU [79% vs. 15%, p < 0.001]. Of those with VOD, 78% required peritoneal drainage, 17% pleural effusion drainage, and 56% respiratory failure. All patients with VOD survived to discharge and to Day +100. In allo‐recipients, OS at Day +365, cumulative incidence of Grade II–IV acute graft‐versus‐host disease (aGVHD) at Day +100, and chronic graft‐versus‐host disease (cGVHD) at Day +365 were similar between those with and without VOD. Median length of stay was longer in those with VOD [60.5 vs. 38 days, p < 0.001]. More patients retrospectively met criteria for VOD than were clinically diagnosed. Conclusion: While VOD in very young children can be highly morbid, they have excellent early survival. Retrospective evaluation demonstrates that only some patients who fulfilled VOD criteria were clinically diagnosed.
- 20 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31617
Bacterial and Parasitic Stool Studies Have Limited Utility in Pediatric Hematopoietic Stem Cell Transplant Patients
Background: Diarrhea is a common complication among pediatric hematopoietic stem cell transplantation (HCT) recipients. Although many of the cases are secondary to graft‐versus‐host disease (GVHD), stool microbiological studies are often performed to evaluate an underlying infectious etiology. The aim of this study was to assess the frequency and utility of stool studies in children who have undergone HCT. Methods: Demographics, clinical characteristics, and stool study results (viral, parasitic, and bacterial) of all patients who underwent HCT at a large, academic, freestanding children's hospital between January 2006 and December 2023 were obtained. Statistical analysis conducted included t tests, chi‐square, and linear regression. Results: Overall, 1381 HCT recipients (9.2 ± 6.6 years) were included. Altogether, 6509 stool studies were obtained among 741 (54%) patients. Salmonella , Shigella , Yersinia , Campylobacter , and Escherichia coli (SSYCE) studies were sent on 363 (26%, 2252 studies) patients with 1 (0.04%) positive result. Clostridium difficile was sent on 706 (51%, 2055 studies) patients, with 156 positive studies (7.6%). Stool ova and parasite testing was sent on 143 (10%, 242 studies) patients, with two positive results (0.8%). Viral studies were sent on 638 (46%, 1960 studies) patients, with 107 positive studies (5.5%). Conclusions: While testing for Clostridium difficile and enteric viruses may have value in the work‐up of pediatric HCT patients, SSYCE and O&P studies hold little to no value. Clinical practices surrounding routine stool microbiological studies should be reconsidered.
- 20 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31617
Bacterial and Parasitic Stool Studies Have Limited Utility in Pediatric Hematopoietic Stem Cell Transplant Patients
Background: Diarrhea is a common complication among pediatric hematopoietic stem cell transplantation (HCT) recipients. Although many of the cases are secondary to graft‐versus‐host disease (GVHD), stool microbiological studies are often performed to evaluate an underlying infectious etiology. The aim of this study was to assess the frequency and utility of stool studies in children who have undergone HCT. Methods: Demographics, clinical characteristics, and stool study results (viral, parasitic, and bacterial) of all patients who underwent HCT at a large, academic, freestanding children's hospital between January 2006 and December 2023 were obtained. Statistical analysis conducted included t tests, chi‐square, and linear regression. Results: Overall, 1381 HCT recipients (9.2 ± 6.6 years) were included. Altogether, 6509 stool studies were obtained among 741 (54%) patients. Salmonella , Shigella , Yersinia , Campylobacter , and Escherichia coli (SSYCE) studies were sent on 363 (26%, 2252 studies) patients with 1 (0.04%) positive result. Clostridium difficile was sent on 706 (51%, 2055 studies) patients, with 156 positive studies (7.6%). Stool ova and parasite testing was sent on 143 (10%, 242 studies) patients, with two positive results (0.8%). Viral studies were sent on 638 (46%, 1960 studies) patients, with 107 positive studies (5.5%). Conclusions: While testing for Clostridium difficile and enteric viruses may have value in the work‐up of pediatric HCT patients, SSYCE and O&P studies hold little to no value. Clinical practices surrounding routine stool microbiological studies should be reconsidered.
- Open Access
- 12 February 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (5) , 297.e1-297.e15
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part III. Long-Term Impact of Chronic Graft-versus-Host Disease on Endocrinologic, Cardiovascular, and Metabolic Outcomes in Survivors of Pediatric Hematopoietic Cell Transplantation
- 12 February 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (5) , 297.e1-297.e15
Open AccessPediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part III. Long-Term Impact of Chronic Graft-versus-Host Disease on Endocrinologic, Cardiovascular, and Metabolic Outcomes in Survivors of Pediatric Hematopoietic Cell Transplantation
- Open Access
- 27 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (4) , 224.e1-224.e13
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes
- 27 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (4) , 224.e1-224.e13
Open AccessPediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part IV. Patient Important Outcomes
- Open Access
- 17 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (2) , 69.e1-69.e18
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part I. Phases of Chronic GVHD, Supportive Care, and Systemic Therapy Discontinuation
- 17 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (2) , 69.e1-69.e18
Open AccessPediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-Versus-Host Disease Survivorship After Hematopoietic Cell Transplantation: Part I. Phases of Chronic GVHD, Supportive Care, and Systemic Therapy Discontinuation
- Top Cited Papers
- 10 October 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (14) , 1302-1312
Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Cerebral adrenoleukodystrophy is a severe form of X-linked adrenoleukodystrophy characterized by white-matter disease, loss of neurologic function, and early death. Elivaldogene autotemcel (eli-cel) gene therapy, which consists of autologous CD34+ cells transduced with Lenti-D lentiviral vector containing ABCD1 complementary DNA, is being tested in persons with cerebral adrenoleukodystrophy. In a phase 2-3 study, we evaluated the efficacy and safety of eli-cel therapy in boys with early-stage cerebral adrenoleukodystrophy and evidence of active inflammation on magnetic resonance imaging (MRI). The primary efficacy end point was survival without any of six major functional disabilities at month 24. The secondary end points included overall survival at month 24 and the change from baseline to month 24 in the total neurologic function score. A total of 32 patients received eli-cel; 29 patients (91%) completed the 24-month study and are being monitored in the long-term follow-up study. At month 24, none of these 29 patients had major functional disabilities; overall survival was 94%. At the most recent assessment (median follow-up, 6 years), the neurologic function score was stable as compared with the baseline score in 30 of 32 patients (94%); 26 patients (81%) had no major functional disabilities. Four patients had adverse events that were directly related to eli-cel. Myelodysplastic syndrome (MDS) with excess blasts developed in 1 patient at month 92; the patient underwent allogeneic hematopoietic stem-cell transplantation and did not have MDS at the most recent follow-up. At a median follow-up of 6 years after lentiviral gene therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities had no major functional disabilities. However, insertional oncogenesis is an ongoing risk associated with the integration of viral vectors. (Funded by Bluebird Bio; ALD-102 and LTF-304 ClinicalTrials.gov numbers NCT01896102 and NCT02698579, respectively.).
- 10 October 2024
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 391 (14) , 1302-1312
Top Cited PapersLentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Cerebral adrenoleukodystrophy is a severe form of X-linked adrenoleukodystrophy characterized by white-matter disease, loss of neurologic function, and early death. Elivaldogene autotemcel (eli-cel) gene therapy, which consists of autologous CD34+ cells transduced with Lenti-D lentiviral vector containing ABCD1 complementary DNA, is being tested in persons with cerebral adrenoleukodystrophy. In a phase 2-3 study, we evaluated the efficacy and safety of eli-cel therapy in boys with early-stage cerebral adrenoleukodystrophy and evidence of active inflammation on magnetic resonance imaging (MRI). The primary efficacy end point was survival without any of six major functional disabilities at month 24. The secondary end points included overall survival at month 24 and the change from baseline to month 24 in the total neurologic function score. A total of 32 patients received eli-cel; 29 patients (91%) completed the 24-month study and are being monitored in the long-term follow-up study. At month 24, none of these 29 patients had major functional disabilities; overall survival was 94%. At the most recent assessment (median follow-up, 6 years), the neurologic function score was stable as compared with the baseline score in 30 of 32 patients (94%); 26 patients (81%) had no major functional disabilities. Four patients had adverse events that were directly related to eli-cel. Myelodysplastic syndrome (MDS) with excess blasts developed in 1 patient at month 92; the patient underwent allogeneic hematopoietic stem-cell transplantation and did not have MDS at the most recent follow-up. At a median follow-up of 6 years after lentiviral gene therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities had no major functional disabilities. However, insertional oncogenesis is an ongoing risk associated with the integration of viral vectors. (Funded by Bluebird Bio; ALD-102 and LTF-304 ClinicalTrials.gov numbers NCT01896102 and NCT02698579, respectively.).